Status:
COMPLETED
Adjuvant Immune Checkpoint Inhibitors in Postoperative Hepatocellular Carcinoma
Lead Sponsor:
Guangxi Medical University
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
18-75 years
Brief Summary
Though hepatectomy is the best treatment for patients with hepatocellular carcinoma (HCC), the 5-years recurrence-free survival is lower than 30%. In recent years, several immune checkpoint inhibitors...
Detailed Description
Hepatic resection is the best treatment for patients with early stage hepatocellular carcinoma (HCC) or selected intermediate or advanced disease. However, the postoperative 5-years recurrent rate is ...
Eligibility Criteria
Inclusion
- Underwent curative hepatectomy;
- Diagnosis of HCC was confirmed by postoperative histopathology;
- Liver function Child-Pugh A or B;
- Performance status score 0 or 1
- With high risk factor of HCC recurrence, such as tumor size ≥ 5 cm, multinodular, macrovascular invasion or microvascular invasion; Receive immune checkpoint inhibitors based adjuvant therapy.
Exclusion
- Receive neoadjuvant immune checkpoint inhibitors therapy.
Key Trial Info
Start Date :
March 3 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 17 2023
Estimated Enrollment :
517 Patients enrolled
Trial Details
Trial ID
NCT05221398
Start Date
March 3 2019
End Date
March 17 2023
Last Update
September 25 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Jian-Hong Zhong
Nanning, Guangxi, China, 530021